Lung Transplantation Clinical Trial
Official title:
Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation
Chronic organ dysfunction after lung transplantation (BOS) is the most common cause of death
in long-term survivors after lung transplantation and refractory to most interventions.
Early markers will be established in this project study to overcome the problem of disease
recognition when impairment of graft function is already taken place. Long-term longitudinal
monitoring in stable recipients of innovative markers of airway inflammation and ventilation
and new imaging techniques will define different entities of chronic organ dysfunction after
LTx. A database and specimen service unit for further projects will be created.
Hypothesis: This project will reveal new markers and imaging tools in recipients who develop
BOS after lung transplantation. These tools will allow earlier diagnosis and more accurate
monitoring of the disease process. Different patterns of the disease will be characterized.
Chronic organ dysfunction of the lung allograft is the most common cause of death in lung
transplant recipients after the first postoperative year and is a major cause of morbidity
in the long-term care. It affects every second recipient surviving 5 years after
transplantation (Boehler, Estenne 2003). Obliterative bronchiolitis (OB) is the
histo-pathological process underlying chronic organ dysfunction after LTx. Bronchiolitis
obliterans syndrome (BOS) is the clinical definition of chronic organ dysfunction following
lung transplantation (LTx) and refers to a progressive obstructive ventilatory disorder.
Staging is performed according to baseline values of forced expiratory volume after LTx
(Estenne et al. 2001).
Excessive immunosuppression may be deleterious by increasing the risk of infection, thereby
triggering innate and adaptive immunity. BOS is progressive in most of the cases with
stabilisation in some. Different clinical entities are found according to time of onset,
speed of decline in graft function (Jackson et al. 2002), ventilatory patterns, findings on
imaging studies (Pakhale et al 2005, Choi et al 2003) and response to macrolides (Gerhardt
et al. 2003). Exhaled biomarkers are promising markers of disease activity in pats with BOS
(an Muylem 2007, Brugiere et al 2005) Alloimmune-independent and -dependent mechanisms
produce injuries and inflammation of epithelial cells and subepithelial structures, leading
to aberrant tissue repair (Nicod et al 2006). The triggering of innate immunity by various
infections (especially respiratory viruses, Khalifah et al 2004) or chemical injuries (e.g.
gastroesophageal reflux or aspiration, Palmer et al. 2000), may lead to the release of
danger signals that are able to activate dendritic cells, a crucial link with adaptive
immunity. Inflammation can also increase the expression and display of major
histocompatibility alloantigens and thus favor the initiation of rejection episodes. The
injuries evoke a proinflammatory response and cellular infiltration that leads to excessive
fibroproliferation and results in matrix deposition and vascular remodelling. These
phenomena may be limited in time and location or may be protracted. Reducing the risk of
alloimmune-independent factors may be as important as treating acute episodes of lung
rejection.
Newpotential therapeutic targets are emerging from the research performed on leukotriene
receptors, chemokine receptors, and growth factors. Neutralizing these molecules may reduce
the initial mononuclear and polynuclear infiltrates or the subsequent fibroproliferative
process and the neovascular changes, feeding this process. (Nicod 2006). Macrolides are
promising new agents which partially reverse loss of graft function in a subgroup of
patients, which may change definition of BOS in the near future (Gerhardt et al 2003).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02581111 -
Naloxone for Optimizing Hypoxemia Of Lung Donors
|
Phase 2/Phase 3 | |
Recruiting |
NCT02177916 -
Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation
|
N/A | |
Not yet recruiting |
NCT01394835 -
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients
|
Phase 2 | |
Completed |
NCT01204970 -
Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients
|
N/A | |
Not yet recruiting |
NCT01162148 -
Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation
|
N/A | |
Active, not recruiting |
NCT00980967 -
Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study
|
N/A | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Recruiting |
NCT00163696 -
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease
|
N/A | |
Completed |
NCT00177684 -
Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
|
Phase 3 | |
Completed |
NCT00163891 -
Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients
|
N/A | |
Completed |
NCT03668483 -
Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx
|
N/A | |
Not yet recruiting |
NCT02855372 -
Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)
|
N/A | |
Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Completed |
NCT01212406 -
Vitamin D in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Not yet recruiting |
NCT00808600 -
Empowerment of Lung and Heart-lung Transplant Patients
|
N/A | |
Completed |
NCT00553397 -
Live Lung Donor Retrospective Study
|
N/A | |
Completed |
NCT00402805 -
Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy
|
Phase 4 | |
Terminated |
NCT00235651 -
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
|
Phase 3 | |
Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
Active, not recruiting |
NCT02936505 -
Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.
|
N/A |